Press Releases

"Due to the lack of transparency, these price concessions are often withheld from patients and payers, increasing PBM profits while failing to decrease drug costs. H.R.

". . . for too long, drug manufacturers have been allowed to game the system by submitting numerous or baseless, bogus petitions simply so the FDA will delay competing manufacturers’ approvals. . . . The Stop STALLING Act is sound, bipartisan legislation that promises to stop this problem for good."

". . . if the branded manufacturer denies the provision of samples, it can delay its competitor’s approval and prop up its own drug’s high costs. This should not be happening. . . . The CREATES Act will prevent this kind of gaming and make sure that generic and biosimilar manufacturers can gain samples to complete testing and win FDA approvals."

"The Preserve Access to Affordable Generics and Biosimilars Act would . . .  accelerate the lowering of prescription drug prices in America. . . . [and] prevent anticompetitive settlements that line drug company pockets while consumers pay the bill."

“The Prescription Pricing for the People Act of 2019 would shed light on how PBMs are affecting prescription costs and patient choice. This would support Congress as it crafts evidence-based solutions to address the anticompetitive role PBMs play as pharmaceutical costs continue to rise.”